Serotonergic dysfunction may contribute to negative mood states in affective disorders. Some in vivo imaging studies showed reduced availability of serotonin transporters (5-HTT) in the brainstem and thalamus of patients with major depression. We tested the hypothesis that 5-HTT availability is reduced in unmedicated unipolar patients with major depression compared to healthy control subjects matched for gender, age, genotype and smoking status. Availability of 5-HTT was measured in vivo with positron emission tomography and [
Introduction
Serotonin transporters (5-HTT) are in the focus of research on the neurobiological correlates of major depression, because several antidepressive drugs block serotonin reuptake and thus alleviate negative mood states. [1] [2] [3] Moreover, Asberg et al. 4, 5 showed that serotonin turnover rates as assessed with the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) are reduced in major depression and increase with recovery. Brain imaging studies in major depression 6, 7 and seasonal affective disorder 8 revealed a reduction in binding of the radioligand [ 123 I]b-CIT to 5-HTT in the diencephalon and/or brainstem. However, the radioligand b-CIT competes with endogenous serotonin for binding to central serotonin transporters (SERTs). 9, 10 In accordance with this hypothesis, a high serotonin turnover rate as indicated by elevated cerebrospinal fluid 5-HIAA concentrations was negatively correlated with SERT availability in humans and nonhuman primates. 11, 12 Moreover, b-CIT also binds to dopamine and norepinephrine transporters. 9, 13, 14 As a result, b-CIT binding to 5-HTT can be assessed only in brain areas where dopamine transporters are rare and where the radioligand is displaced exclusively by selective serotonin reuptake inhibitors. 3, 9, 10, 15 Using [ 11 C]McN, a positron emission tomography (PET) ligand with selective affinity for 5-HTT that is assumed to be not displaceable by endogenous serotonin, 16 Parsey et al. 17 observed reduced midbrain and amygdala 5-HTT availability in a group of 25 patients with major depression, while Ichimiya et al. 18 19 also binds selectively to 5-HTT 20 and is also assumed to measure 5-HTT availability independent from synaptic levels of endogenous serotonin. 21 Using this tracer, Meyer and co-workers observed unaltered binding in various subcortical and cortical regions, including the thalamus and midbrain, with the exception of a subgroup of patients with highly negativistic attitudes that displayed increased 5-HTT binding potential. 22 As Meyer pointed out, 23 reductions in 5-HTT availability might depend on comorbidity such as anxiety. Therefore, this study was designed to assess whether low 5-HTT availability in the midbrain, thalamus and amygdala of medication-free patients with major depression is associated with the severity of anxiety and related to certain personality traits.
Age, gender, smoking status 7, 24 and the genetic constitution of the 5-HTT regulatory region (5-HTTLPR) [25] [26] [27] [28] [29] may affect transporter availability and it has been suggested that discrepancies in the literature may in part be explained by interactions between these covariates. 7 Therefore, we compared central SERTs in patients with control subjects individually matched for gender, 5-HTTLPR genotype and smoking status.
Materials and methods

Patients and control subjects
Ten patients with unipolar major depression were included in this study (Table 1) . Patients suffered from unipolar major depression according to ICD-10 and DSM-IV criteria and had no other psychiatric axis I disorder, no past history of drug dependence or current drug abuse (random urine drug testing and Structured Clinical Interview for DSM-IV Personality Disorders (SCID) interview 30 ) except for nicotine abuse. The severity of depression was assessed with Beck's Depression Inventory (BDI) 31, 32 and the severity of the state anxiety with Spielberger's State-Trait Anxiety Inventory (STAI). 33 Personality traits were measured with the Temperament and Character Inventory (TCI). 34 The subjects were recruited before starting antidepressive medication (N = 3) or during a washout period (N = 7) before switching antidepressants. Participation in the study was not the reason for withdrawal from antidepressant treatment. Patients had received either monotherapies or combinations of Mirtazapin (N = 2), selective serotonin reuptake inhibitors (citalopram N = 4, sertralin N = 1, fluvoxamin N = 1), tricyclic antidepressants (trimipramin N = 1, doxepin N = 1) or reboxetin (N = 1). Withdrawal from antidepressants started at least five plasma half-lives (range 5-17 days, mean 9 days, s.d. 4) before PET scans. Two patients were on neuroleptics (olanzapine, sulpirid or promethazin), but had stopped intake more than 8 days before.
Nineteen age-matched healthy subjects served as control subjects. They had no psychiatric axis I or II disorder (SCID I and II interview). 30, 35 Random urine and blood testing was performed to exclude current alcohol or drug abuse except for nicotine abuse. A subgroup of 17 control subjects was selected to individually match 5-HTTLPR genotype (LL versus Sx), smoking status and age of each depressed patient. To avoid potential effects of nicotine withdrawal, all subjects were allowed to smoke freely until they entered the scanner. For two depressed patients we could not find an individually matching partner due to the smaller number of nonsmoking LL carriers in our control group. These patients were included only in the multiple regression analysis, not for calculation of the weighted mean as described below. The study was approved by the ethics committee of the University of Heidelberg and Tü bingen and was in accordance with the Helsinki Declaration. After complete description of the study to the subjects, written informed consent was obtained. Patients described the study as mildly uncomfortable, particularly resting in the somewhat confined scanner. Blood draws and testing procedure were experienced as time consuming rather than unpleasant.
PET methods [ 11 C]DASB was synthesized as previously described. 36 After intravenous bolus injection of 740 MBq [ 11 C]DASB, the distribution of cerebral radioactivity was measured with a GE Advance PET scanner (GE Medical Systems, Milwaukee, WI, USA, axial field of view 15 cm) in two-dimension acquisition mode. For attenuation correction, a transmission scan with 500 000 kilo counts was used. Three external markers were attached to the skull to support realignment. We used filtered backprojection (128 Â 128 pixel = 30 cm) with a Hanning filter (cutoff 4.6 mm) to reconstruct our images. Realignment, stereotactic normalization and Gaussian smoothing (10 mm full-width half maximum) were done with matlab and the software SPM2 (Wellcome Department of Imaging Neuroscience, London, UK). For stereotactic normalization we compared early summation images (0-5 min p.i.) with the standard PET perfusion template provided with SPM. All image data were spatially smoothed before region of interest (ROI) and voxelwise statistical analysis. The purpose for this was to improve the signal-to-noise ratio and to compensate for anatomical variability that was not corrected by SPM's normalization. The latter might be especially relevant for quantification of regions such as the midbrain, where the highest density of binding sites is located in nuclei that cannot easily be anatomically delineated.
in the first tissue compartment, B max = receptor concentration, K D = dissociation constant) was calculated for each voxel and for three-dimensional ROIs of the midbrain, the thalamus and the amygdala with the 'multilinear reference tissue model 2' (MRTM2). 37 The thalamus ROI (2 Â 0.98 ml) is part of a MNI space ROI set that is locally established at the PET center. The midbrain ROI was derived from isocontours in the between-subject mean image (mean BP ND > 2.5) and thus represents the part of the midbrain with the highest density of 5-HTT (size 1.04 ml), particularly the raphe area. The amygdala ROI (4 Â 4 Â 4 mm) was placed in the amygdala area where the mean image showed a local maximum of BP ND . Time-activity curves (TACs) for the reference tissue were derived from a three-dimensional mask of the cerebellum, excluding the vermis. 38 The washout from the reference tissue k 2 0 , which is used as a parameter in MRTM2, was calculated for each patient as previously described (Reimold et al., submitted).
Genotyping
We assessed the promotor genotype of the 5-HTT gene with polymerase chain reaction (PCR) using oligonucleotide primers (stpr5, 5 0 -GGCGTTGCCGCTCTGAATGC; int1, 5 0 -CAGGGGAGATCCTGGGAGGA), as described previously. 26 PCR amplification was carried out in a final volume of 30 ml consisting of 50 ng genomic DNA, 2. 
Statistical analysis
Statistical analyses were calculated with the software JMP 5.1 (SAS Institute). Student's t-test for independent samples was used to assess whether patients suffering from major depression display reduced DASB binding in the midbrain, thalamus and amygdala as compared to the control subjects. To account for the possible confounding variables gender, 5-HTTLPR genotype, smoking status and age, we pursued two different approaches: first, we assigned all subjects (patients and controls) to groups according to their categorical parameters (Table 1) , then each control subject was given a weighting factor to achieve the same relative group weight for patients and controls. The benefit from this approach is that interactions between the confounding variables are allowed; while the drawback of this approach is that two patients and two control subjects could not be included in the analysis due to missing individually matching partners. Second, we calculated a multiple regression for all subjects, investigating the diagnosis effect corrected for gender, genotype, smoking status and age. Age dependence among healthy controls was assessed by a general linear model accounting for age, gender, genotype and smoking status, and was used to calculate age-corrected values of BP ND for each patient. We tested the hypothesis that BP ND in the thalamus, midbrain and amygdala is negatively correlated with the severity of depression (BDI) and anxiety (STAI). In those regions that showed significantly reduced BP ND in depressed patients (that is, in the thalamus), we also explored positive and negative correlations with personality traits (TCI).
To correct the family-wise error rate for multiple testing in the strong sense, we used the method of Bonferroni-Holm. When testing diagnosis effects, we assessed three ROIs by two analyses each (weighted mean analysis and multiple regression), accordingly, we corrected for six independent comparisons. The same factor was used for correlation analyses (three ROI and two clinical variables: STAI and BDI).
To more precisely locate group differences and to exploratively search for group differences outside our ROIs, we calculated a voxel-wise statistical analysis using the publicly available software SPM2. For voxel-wise statistical analysis, we used the parametric images described above and calculated a linear model with the same confounders as in the ROI analysis (age, gender, genotype, smoking status). Since the goal of this analysis was to exploratively search for additional clusters, we chose the voxellevel threshold (P = 0.01) and the extent threshold (10 voxels) to be rather liberal. All clusters were transformed to masked contrast images by applying an algorithm previously described 39 using the publicly available SPM toolbox MASCOI (author Matthias Reimold) and a 'secondary threshold' of P = 0.05. This had the effect of improving anatomical precision by removing artifacts from a variability of the local variance.
Results
Group differences in serotonin transporter availability
Demographic and clinical data of the study population are given in Table 1 . By applying the weights given in Table 1 , group mean characteristics can be given without further correcting for age, gender, genotype and smoking status. Unless stated explicitly, reported group mean characteristics (mean BP ND , average TAC, t-statistic of the group difference) refer to weighted subjects.
Parametric images of DASB BP ND show decreased SERT availability in the thalamus of patients with major depression (Figure 1 ). Color-coded voxel values reflect the weighted mean BP ND in depressed patients (Figure 1, left) and healthy controls (Figure 1 , right) at z = 0 (MNI space). ROI analysis (Figure 1 ; Table 1 ) confirmed significant group differences in the thalamus (patients: 1.07 ± 0.23, weighted mean 1.13; controls: 1.35 ± 0.18, weighted mean 1.35; Student's t = 2.82, d.f. = 23, P = 0.0049), surviving Bonferroni correction for multiple testing (P corr = 0.024). Group differences in the midbrain (patients: 2.56 ± 0.59, weighted mean 2.64; controls: 2.86±0.58, weighted mean 2.80, P = 0.26) and in the amygdala (patients: 1.04 ± 0.24, weighted mean 1.08; controls: 1.12 ± 0.24, weighted mean 1.09, P = 0.45) were smaller and not statistically significant.
Average TACs in the thalamus are shown in Figure 2 . Before calculating the average radioactivity concentration of each group, the individual curves were normalized by cerebellar radioactivity concentration (to allow for a better visual comparison of the curves) and weighted as described above. The cerebellar curves showed only small differences between groups, corresponding with the fact that both groups were comparable with respect to reference tissue washout (patients: Before averaging (mean image, ROI mean), subjects were weighted to account for the different number of subjects in each matching cell (genotype, gender, smoking status, cf. Table 1 ).
In the multiple regression analysis (10 patients versus 19 control subjects, controlling for age, gender, genotype and smoking status), the diagnosis effect in the thalamus remained significant at P = 0.0016 unilateral (least square (LS) means±s.e.: 1.09±0.05 in patients versus 1.31±0.04 in controls, P corr = 0.01). The other model effects (except age) were not significant. Among male subjects (5 patients versus 11 controls), multiple regression (nuisance variables: age, genotype and smoking status) also revealed decreased 5-HTT in the thalamus of depressed patients (P = 0.05 unilateral: LS means±s.e.: 1.18±0.08 in patients versus 1.3 ± 60.07 in healthy controls). Multiple regression among control subjects yielded an age-related decline of 0.0135 per year (P = 0.0003).
Explorative voxel-wise analysis of group differences with SPM and MASCOI (Figure 3 ) revealed one larger cluster (1102 voxels) ranging from the midbrain (where the maximum contrast CON max was located, MNI (À2/ À18/À8)) to the bilateral thalamus, where the majority of voxels (691) and the highest level of significance were located (original t-map cluster: 637 voxels = 5.1 ml, T max = 4.15 at MNI (6/À16/8), regional least significant difference DBP ND = 0.382). Further clusters were found in the left putamen (T max 3.46, size 121 voxels, CON max at MNI (À18/6/À6)), the right insula (T max = 2.63, size 57 voxels, CON max at MNI (28/14/2)), the anterior cingulate (T max = 3.71, size 18 voxels, CON max at MNI (0/36/16)) and the cingulate gyrus (T max = 3.32, size 15 voxels, CON max at MNI (2/À14/42)).
Correlations between serotonin transporter availability and clinical variables Severity of depression (BDI score), state anxiety (STAI) and harm avoidance (TCI) were significantly increased in patients suffering from major depression compared with healthy control subjects ( Table 1) . Among patients, reduced 5-HTT availability in the thalamus was significantly correlated with state anxiety (STAI score; r = À0.78, P = 0.004, P corr = 0.02); the correlation with severity of clinical depression (BDI score) was weaker and not significant (r = À0.44, P = 0.10). The same pattern was found for 5-HTT availability in the midbrain (STAI: r = À0.78, P = 0.004, P corr = 0.02; BDI: r = À0.52, P = 0.06) and the amygdala (STAI: r = À0.80, P = 0.003, P corr = 0.02; BDI: r = À0.58, P = 0.04). To test if reduced thalamic 5-HTT availability in patients as compared to healthy controls can be attributed to their diagnosis or rather reflects the higher level of anxiety, we calculated a multiple regression analysis accounting for age, diagnosis and anxiety. In all 29 subjects, this model predicted 63% of 5-HTT variance with age (r = À0.65, P = 0.0001) and anxiety (r = À0.45, P = 0.008) being the only significant effects. There was no additional diagnosis effect (LS means 1.24 in patients versus 1.25 in controls). Accordingly, the correlation between age-corrected 5-HTT and STAI was only little weaker when calculated from all subjects (Figure 4 , N = 29, r = À0.69, P < 0.0001) than from patients alone (r = À0.78, see above).
Additional explorative correlation analyses showed that in the patient group, reduced 5-HTT availability in the thalamus was trend-wise associated with low ]DASB time-activity curves (TACs, average across all subjects) in patients with major depression (DEP) and healthy controls (HC). To allow for a better visual comparison of the shape of the TAC, TACs were normalized to cerebellar radioactivity concentration. As shown in Figure 1 , individual data were weighted to account for genotype, gender and smoking status. Figure 3 Additional explorative voxel-wise analysis of group differences (patients versus controls). Correcting for age, gender, genotype and smoking status, SPM revealed several clusters with decreased serotonin transporter availability in patients with major depression (surviving a voxellevel threshold of P = 0.01). To improve spatial precision, we transformed SPM's t-map to a masked contrast using a previously described algorithm. 39 The largest cluster (8.8 ml; T max 4.1) ranged from midbrain (maximum contrast CON max at MNI (À2/À18/À8)) to the bilateral thalamus (where 63% of the voxels were located). Further clusters were found in the left putamen, the right insula, two clusters within the cingulate gyrus (BA24).
scores of novelty-seeking (r = 0.56, P = 0.11). In control subjects, we found no significant correlations between 5-HTT availability in the thalamus and severity of anxiety, depression or personality traits.
Discussion
In this study, patients suffering from unipolar major depression showed reduced SERT (5-HTT) availability in the thalamus compared to healthy control subjects individually matched for age, smoking status, 5-HTT genotype and gender. In accordance with our hypothesis, we observed a significant negative correlation between SERT availability in the thalamus and the severity of anxiety (STAI) and to a lower degree with the severity of depressed mood (BDI). Furthermore, low SERT availability in the thalamus was associated with low levels of noveltyseeking. Reduced serotonin reuptake capacity in the thalamus may interfere with activity and excitability of thalamic and cortical neurons 40 and thus contributes to negative mood states such as anxiety and to a low tendency for seeking new experiences.
Our results differ from those of Meyer and coworkers, 22 ,41 who did not observe a significant difference in DASB binding in patients suffering from major depression compared to healthy control subjects. However, Meyer and co-workers excluded patients suffering from anxiety disorders, while in our study, the severity of anxiety rather than depressive mood per se was associated with low 5-HTT availability in the thalamus.
Our finding is in agreement with a series of singlephoton emission computed tomography (SPECT) studies that used the radioligand b-CIT and observed reduced SERT availability in the diencephalon, including the thalamus, and/or brainstem of patients suffering from major depression 6, 7 or seasonal affective disorder. 8 However, b-CIT competes with endogenous serotonin for binding, 10 thus it remained controversial whether published reductions in b-CIT binding reflect reduced density of 5-HTT or increased levels of synaptic serotonin. In vitro studies showed that the radioligand DASB is not displaced by endogenous serotonin from its binding site at the human SERT. 21 Thus, the presented data provide further evidence that reported reductions in b-CIT binding are due to reduced density of 5-HTT.
To our knowledge, the study of Malison et al. 6 has been the only study to date, where individual anxiety scores were compared with 5-HTT availability. In agreement with our data, Malison et al. reported about a negative correlation between anxiety (Hamilton anxiety rating scale) and brainstem b-CIT binding (r = À0.32), however this correlation was not statistically significant (N = 15) and 5-HTT availability in other regions was not investigated.
Is has been suggested that interactions between gender, age and depression partly explain discrepancies in the literature: Staley et al. 7 observed that b-CIT binding was reduced particularly in the diencephalon of younger female patients. While our individual matching scheme allows statistical interactions between all categorical confounders (gender, genotype, smoking status), we cannot correct for hypothetic differences in age effects between the different matching cells. This could be a limitation of our study, however, while Staley et al. 7 reported reduced 5-HTT in younger female patients, our female patients (weighted mean: 51 years) were older than our female controls (weighted mean: 39.3 years), so that these age differences cannot explain our findings. Furthermore, we observed reduced thalamic 5-HTT binding also in male patients. However, due to the limited number of patients, our present study does not allow to draw reliable conclusions about gender effects and interactions with smoking, age and depression. Another limitation of the present study is that we cannot rule out that SERTs remained downregulated after previous exposure to antidepressive medication. 42, 43 Contrary to our hypothesis, ROI analysis did not show significant differences between patients suffering from major depression and healthy control subjects in the midbrain or amygdala. In the amygdala, increased activation elicited by aversive stimuli was observed among subjects who carried a 5-HTT genotype that was associated with low SERT expression. [44] [45] [46] However, it is currently not clear whether the assessed 5-HTT genotype exerts its effect via developmental or current expression of 5-HTT in the amygdala or in some other serotonergic brain area. 47, 48 Published PET and SPECT studies that revealed reductions in 5-HTT availability differ with respect to the described anatomical pattern. In agreement with the present study, Staley et al. 7 observed reductions in the diencephalon including the thalamus, but not in the brainstem, while Parsey et al. 17 observed a significant reduction in SERT availability in midbrain and amygdala, but not in the thalamus. Malison et al. 6 also observed reductions in the Correlation between 5-HTT and anxiety M Reimold et al brainstem but do not report about 5-HTT availability in other regions. The observed correlation between 5-HTT availability and severity of anxiety in the present study suggests that all these regions are affected in major depression, though group differences may not reach statistical significance due to signal-to-noise issues. The latter may include methodological aspects such as ROI definitions and tracer properties 19 as well as clinical covariates (for example, genotype, smoking status). Explorative voxelwise analysis indeed showed further regions with reduced 5-HTT availability in patients suffering from major depression, that is, the midbrain (a cluster that extended into the bilateral thalamus), the left putamen, the right insula, the anterior cingulate and the cingulate gyrus.
Altogether, our study supports the hypothesis that serotonin dysfunction is associated with negative mood states. 11, [49] [50] [51] Specifically, it suggests that anxiety is increased and novelty-seeking is decreased with low levels of SERT availability in the thalamus of patients suffering from major depression, who were matched with healthy control subjects for age, 5-HTT genotype, gender and smoking status. Further studies can assess the interaction between in vivo thalamic 5-HTT availability and central processing of affective stimuli in limbic brain areas in healthy controls and patients with major depression.
